This study aims to assess the effcacy and safety of doripenem on treating patients with\nacute bacterial infections. The Pubmed, Embase, and Cochrane databases were searched up to April\n2019. Only randomized clinical trials comparing doripenem and other comparators for the treatment\nof acute bacterial infection were included. The primary outcome was the clinical success rate and\nthe secondary outcomes were microbiological eradication rate and risk of adverse events. Eight\nrandomized controlled trials (RCTs) were included. Overall, doripenem had a similar clinical success\nrate with comparators (odds ratio [OR], 1.15; 95% CI, 0.79-1.66, I2 = 58%). Similar clinical success\nrates were noted between doripenem and comparators for pneumonia (OR, 0.84; 95% CI, 0.46-1.53,\nI^2 = 72%) and for intra-abdominal infections (OR, 1.00; 95% CI, 0.57-1.72). For complicated urinary\ntract infection, doripenem was associated with higher success rate than comparators (OR, 1.89, 95%\nCI, 1.13-3.17, I^2 = 0%). The pool analysis comparing doripenem and other carbapenems showed no\nsignificant differences between each other (OR, 0.96, 95% CI, 0.59-1.58, I^2 = 63%). Doripenem also\nhad a similar microbiological eradication rate with comparators (OR, 1.08; 95% CI, 0.86-1.36, I^2 = 0%).\nFinally, doripenem had a similar risk of treatment-emergent adverse events as comparators (OR, 0.98;\n95% CI, 0.83-1.17, I^2 = 33%). In conclusion, the clinical effcacy of doripenem is as high as that of the\ncomparator drugs in the treatment of acute bacterial infection; furthermore, this antibiotic is as well\ntolerated as the comparators.
Loading....